ArticleJournal of virology2003
Packaging of human chromosome 19-specific adeno-associated virus (AAV) integration sites in AAV virions during AAV wild-type and recombinant AAV vector production.
Article in Journal of virology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- The role of CD4MedComm · 2023Review
- Understanding capsid assembly and genome packaging for adeno-associated viruses.Future virology · 2017Article
- OneBac 2.0: Sf9 Cell Lines for Production of AAV1, AAV2, and AAV8 Vectors with Minimal Encapsidation of Foreign DNA.Human gene therapy methods · 2017Article
- OneBac 2.0: Sf9 Cell Lines for Production of AAV5 Vectors with Enhanced Infectivity and Minimal Encapsidation of Foreign DNA.Human gene therapy · 2015Article
- The Adeno-Associated Virus Genome Packaging Puzzle.Journal of molecular and genetic medicine : an international journal of biomedical research · 2015Article
- Impact of the MRN Complex on Adeno-Associated Virus Integration and Replication during Coinfection with Herpes Simplex Virus 1.Journal of virology · 2015Article
- Strategies to circumvent humoral immunity to adeno-associated viral vectors.Expert opinion on biological therapy · 2015Review
- Adeno-associated virus type 2 wild-type and vector-mediated genomic integration profiles of human diploid fibroblasts analyzed by third-generation PacBio DNA sequencing.Journal of virology · 2014Article
- OneBac: platform for scalable and high-titer production of adeno-associated virus serotype 1-12 vectors for gene therapy.Human gene therapy · 2014Article
- The inside out of lentiviral vectors.Viruses · 2011Review
- Substitution of adeno-associated virus Rep protein binding and nicking sites with human chromosome 19 sequences.Virology journal · 2010Article
- Integration preferences of wildtype AAV-2 for consensus rep-binding sites at numerous loci in the human genome.PLoS pathogens · 2010Article
- Heparin binding induces conformational changes in Adeno-associated virus serotype 2.Journal of structural biology · 2009Article
- Identification of cellular proteins that interact with the adeno-associated virus rep protein.Journal of virology · 2009Article
- Adeno-associated virus site-specific integration is regulated by TRP-185.Journal of virology · 2007Article
- Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver.Journal of virology · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adeno-associated virus type 2 (AAV-2) establishes latency by site-specific integration into a unique locus on human chromosome 19, called AAVS1. During the development of a sensitive real-time PCR assay for site-specific integration, AAV-AAVS1 junctions were reproducibly detected in highly purified AAV wild-type and recombinant AAV vector stocks. A series of controls documented that the junctions were packaged in AAV capsids and were newly generated during a single round of AAV production. Cloned junctions displayed variable AAV sequences fused to AAVS1. These data suggest that packaged junctions represent footprints of AAV integration during productive infection. Apparently, AAV latency established by site-specific integration and the helper virus-dependent, productive AAV cycle are more closely related than previously thought.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.